Verona Pharma Financials

VRNA Stock  USD 57.24  2.41  4.40%   
Based on the key measurements obtained from Verona Pharma's financial statements, Verona Pharma PLC may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At present, Verona Pharma's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 301 M, whereas Total Current Liabilities is forecasted to decline to about 7.7 M. Key indicators impacting Verona Pharma's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.190.2059
Significantly Down
Slightly volatile
Current Ratio40.2538.33
Sufficiently Up
Very volatile
The essential information of the day-to-day investment outlook for Verona Pharma includes many different criteria found on its balance sheet. An individual investor should monitor Verona Pharma's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Verona Pharma.

Net Income

(46.49 Million)

  
Please note, the presentation of Verona Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Verona Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Verona Pharma's management manipulating its earnings.

Verona Pharma Stock Summary

Verona Pharma competes with Ventyx Biosciences, Ideaya Biosciences, Protagonist Therapeutics, Syndax Pharmaceuticals, and Day One. Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom. Verona Pharma is traded on NASDAQ Exchange in the United States.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS9250501064
CUSIP925050106
LocationUnited Kingdom
Business Address3 More London
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.veronapharma.com
Phone44 20 3283 4200
CurrencyUSD - US Dollar

Verona Pharma Key Financial Ratios

Verona Pharma Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets204.2M186.6M259.5M308.1M354.3M372.1M
Net Debt(182.0M)(142.6M)(217.2M)(220.4M)(198.4M)(188.5M)
Retained Earnings(207.1M)(263.7M)(333.1M)(388.4M)(349.6M)(332.1M)
Accounts Payable178K10.0M2.9M3.5M4.0M4.2M
Cash188.0M148.4M227.8M271.8M312.5M328.2M
Net Receivables8.3M15.6M9.3M11.0M12.6M13.2M
Inventory4.5M4.0M2.5M1.01.151.09
Other Current Assets6.3M6.1M5.9M7.0M8.0M8.4M
Total Liab19.4M38.6M29.0M58.8M67.7M71.1M
Total Current Assets202.5M170.1M243.0M289.7M333.2M349.8M
Common Stock31.8M31.9M40.5M42.8M49.2M51.6M
Other Current Liab12.4M22.6M15.2M4.0M4.6M5.9M
Net Tangible Assets42.2M184.3M167.7M229.9M264.4M277.6M
Long Term Debt4.6M4.9M9.8M48.4M55.6M58.4M
Short Term Debt1.6M648K675K1.2M1.4M694.2K
Net Invested Capital189.5M152.9M240.2M297.7M342.3M174.8M

Verona Pharma Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense35K340K521K2.1M2.4M2.5M
Operating Income(74.3M)(73.3M)(66.1M)(67.8M)(61.0M)(58.0M)
Ebit(48.4M)(42.8M)(67.9M)(53.1M)(47.8M)(45.4M)
Ebitda(47.8M)(42.2M)(67.3M)(52.5M)(47.2M)(44.9M)
Income Before Tax(65M)(55.6M)(68.4M)(55.2M)(49.7M)(47.2M)
Net Income(65.1M)(55.6M)(68.7M)(54.4M)(48.9M)(46.5M)
Research Development44.5M79.4M49.3M17.3M19.9M19.8M
Income Tax Expense146K(18K)253K(632.4K)(569.2K)(597.7K)
Gross Profit(627.8K)40M112K(679.6K)(781.6K)(742.5K)
Tax Provision146K(18K)253K555K638.3K670.2K
Interest Income121K14K2.8M11.3M13.0M13.7M
Net Interest Income86K(326K)2.3M9.7M11.1M11.7M

Verona Pharma Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash157.6M(39.6M)79.4M43.9M50.5M53.1M
Free Cash Flow(45.2M)(33.3M)(59.9M)(50.2M)(45.2M)(42.9M)
Other Non Cash Items18K239K4.8M(332.4K)(299.2K)(314.1K)
Capital Expenditures82K12K29K4.074.684.45
Net Income(65.1M)(55.6M)(68.7M)(54.6M)(49.1M)(46.7M)
End Period Cash Flow188.0M148.4M227.8M271.8M312.5M328.2M
Depreciation623K629K636K116K133.4K212.0K
Change To Netincome1.5M21.6M8.1M18.9M21.7M22.8M
Change To Inventory(774.0K)6.9M(4.0M)1.01.151.09
Investments5.3M37.8M9.7M(12K)(29K)0.0

Verona Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Verona Pharma's current stock value. Our valuation model uses many indicators to compare Verona Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Verona Pharma competition to find correlations between indicators driving Verona Pharma's intrinsic value. More Info.
Verona Pharma PLC is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Verona Pharma's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Verona Pharma's earnings, one of the primary drivers of an investment's value.

Verona Pharma PLC Systematic Risk

Verona Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Verona Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-five with a total number of output elements of sixteen. The Beta measures systematic risk based on how returns on Verona Pharma PLC correlated with the market. If Beta is less than 0 Verona Pharma generally moves in the opposite direction as compared to the market. If Verona Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Verona Pharma PLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Verona Pharma is generally in the same direction as the market. If Beta > 1 Verona Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Verona Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Verona Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Verona Pharma growth as a starting point in their analysis.

Price Earnings To Growth Ratio

8.67

At present, Verona Pharma's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.

Verona Pharma January 31, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Verona Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Verona Pharma PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of Verona Pharma PLC based on widely used predictive technical indicators. In general, we focus on analyzing Verona Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Verona Pharma's daily price indicators and compare them against related drivers.

Complementary Tools for Verona Stock analysis

When running Verona Pharma's price analysis, check to measure Verona Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verona Pharma is operating at the current time. Most of Verona Pharma's value examination focuses on studying past and present price action to predict the probability of Verona Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verona Pharma's price. Additionally, you may evaluate how the addition of Verona Pharma to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Equity Valuation
Check real value of public entities based on technical and fundamental data
Money Managers
Screen money managers from public funds and ETFs managed around the world